

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1. (cancelled)
2. (currently amended) A crystalline Form I polymorph of 4-cyclopentyl resorcinol monohydrate that exhibits an X-ray powder diffraction pattern having a characteristic peak expressed in degrees 2θ at approximately 8.1.
3. (cancelled)
4. (original) A crystalline polymorph of 4-cyclopentyl resorcinol monohydrate that exhibits an X-ray powder diffraction pattern having a characteristic peak expressed in degrees 2θ at approximately 23.8.
5. (original) A crystalline polymorph of 4-cyclopentyl resorcinol monohydrate that exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ at approximately 8.1 and 23.8.
6. (original) The crystalline polymorph according to claim 5 that exhibits a characteristic peak expressed in degrees 2θ at approximately 16.2.
7. (original) The crystalline polymorph according to claim 5 which exhibits at least one peak expressed in degrees 2θ at approximately 20.0 and 25.8.
8. (original) The crystalline polymorph according to claim 5 which exhibits at least one peak expressed in degrees 2θ at approximately 13.9, 14.3, 18.4, 19.3, 20.0, 21.3, 25.8 or 26.5.
9. (cancelled)

10. (cancelled)

11. (original) A crystalline polymorph of 4-cyclopentyl resorcinol monohydrate that exhibits a single crystal X-ray crystallographic analysis at 160 K with crystal unit cell parameters that are equal to the following:

Table I
Space Group and Unit Cell Parameters for Form I Polymorph

Form	I
Crystal system	monoclinic
Space group	<i>P</i> 2 ₁ /c

Cell Dimensions

<i>a</i> (Å)	11.313 ± 0.001
<i>b</i> (Å)	7.495 ± 0.001
<i>c</i> (Å)	12.881 ± 0.001
β(°)	110.00 ± 0.01
Volume(Å ³)	987 ± 1
Z(Molecules/unit cell)	4
Density (g/cm ³)	1.27 g/cm ³
Temperature	160 K

12. (currently amended) A method for lightening skin comprising administering a compound according to claim [1] 2 to a patient in need thereof.

13. (currently amended) A method for reducing pigmentation in skin comprising administering a compound according to claim [1] 2 to a patient in need thereof.

14. (currently amended) A pharmaceutical formulation comprising an effective amount of a compound according to claim [1] 2 in admixture with at least one pharmaceutically acceptable carrier.
15. (cancelled)